Trial Profile
A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary) ; Dacarbazine; Paclitaxel; Vemurafenib
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms METRIC
- Sponsors GlaxoSmithKline; GSK; Novartis Pharma A.G.
- 15 Feb 2019 Denmark Finland,Hungary, Ireland, Netherlands Spain, were planned locations as per European Clinical Trials Database record.
- 25 Jan 2019 Results of five-year outcomes from a phase 3 METRIC study published in the European Journal of Cancer.
- 23 Oct 2017 Status changed from active, no longer recruiting to completed.